Valuation: GENFIT

Market Cap 438M 490M 405M 367M 687M 46.63B 698M 4.88B 1.93B 24.39B 1.84B 1.8B 77.22B P/E 2026 *
-422x
P/E 2027 * -895x
Enterprise Value 410M 459M 379M 344M 643M 43.63B 653M 4.57B 1.81B 22.82B 1.72B 1.68B 72.26B EV / Sales 2026 *
5.16x
EV / Sales 2027 * 3.09x
Free-Float
86.79%
Yield 2026 *
-
Yield 2027 * -
1 day+8.56%
1 week+5.67%
Current month-4.13%
1 month-3.35%
3 months-30.28%
6 months+16.97%
Current year+80.63%
1 week 8.47
Extreme 8.47
9.63
1 month 7.72
Extreme 7.72
10.26
Current year 5.05
Extreme 5.05
15.48
1 year 3.4
Extreme 3.4
15.48
3 years 2.62
Extreme 2.62
15.48
5 years 2.62
Extreme 2.62
15.48
10 years 2.62
Extreme 2.62
35.65
Manager TitleAgeSince
Chief Executive Officer 58 15/09/2019
Director of Finance/CFO 52 21/04/2021
Chief Tech/Sci/R&D Officer - 26/11/2025
Director TitleAgeSince
Chairman 70 15/06/2017
Director/Board Member 58 15/06/2017
Director/Board Member 70 15/06/2017
Date Insider Type Main position Quantity % Market Cap. Importance
05/03/26 Exercice

Chief Operating Officer

11,250 0.0225%
05/03/26 Exercice

Chief Operating Officer

7,083 0.0142%
05/03/26 Sell

Chief Operating Officer

7,083 0.0142%
Change 5-day change 1-year change 3-year change Capi.($)
+8.11%+5.67%+159.41%+214.90% 490M
+0.88%-0.34%+40.64%+73.05% 65.28B
-0.69%-0.67%+9.06%+76.30% 54.57B
-0.22%+1.34%+9.47%+101.34% 53.59B
-2.06%+2.90%+24.07%+48.36% 45.03B
-1.79%+0.19%+19.32%+123.62% 42.17B
-1.65%+0.96%+237.56%+823.66% 39.42B
-2.26%-4.14%+15.38%+45.53% 32.71B
-2.70%-10.77%+19.80%-6.47% 24.01B
+0.64%+14.95%+59.95%+49.03% 26.5B
Average -0.13%+2.69%+59.47%+154.93% 38.38B
Weighted average by Cap. -0.89%+2.28%+45.76%+148.42%

Financials

2026 *2027 *
Net sales 79.46M 88.86M 73.51M 66.56M 125M 8.45B 127M 885M 350M 4.42B 333M 326M 14B 128M 143M 118M 107M 200M 13.59B 204M 1.42B 563M 7.11B 536M 525M 22.51B
Net income -1.09M -1.22M -1.01M -916K -1.72M -116M -1.74M -12.18M -4.82M -60.88M -4.59M -4.49M -193M 4.87M 5.44M 4.5M 4.08M 7.63M 518M 7.75M 54.18M 21.43M 271M 20.43M 19.99M 858M
Net Debt -28.18M -31.52M -26.08M -23.61M -44.19M -3B -44.91M -314M -124M -1.57B -118M -116M -4.97B -43.67M -48.83M -40.4M -36.58M -68.46M -4.65B -69.58M -486M -192M -2.43B -183M -179M -7.69B
Projected Income Statement - Annual - GENFIT
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
180
Date Price Change Volume
27/10/26 €9.470 +8.11% 308,316
26/10/26 €8.760 +1.04% 202,679
23/10/26 €8.670 -2.47% 167,768
22/10/26 €8.890 -4.10% 406,182
21/10/26 €9.270 +3.00% 304,234
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - GENFIT
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.760EUR
Average target price
17.48EUR
Spread / Average Target
+99.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GENFIT
  1. Stock Market
  2. Stocks
  3. GNFT Stock